PepsiCo (PEP)

PepsiCo faces significant challenges, particularly from the emerging GLP-1 weight loss drugs, which are impacting its snack sales and overall demand in North America. Recent reports show that while the company has a robust dividend yield of 4% and has historically performed well due to its strong snack portfolio like Frito-Lay, the current market dynamics have led to a lackluster performance, with a year-to-date decline in stock value compared to competitors like Coke. Despite being downgraded and facing a weakening North American consumer, some experts see potential in the stock if it falls further, labeling it as a buying opportunity. Analysts are divided on its valuation, with opinions suggesting it could be undervalued or fairly valued, reinforcing a cautious approach among investors as they await the upcoming earnings report, which could give clearer insights into its future potential.